India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports

BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech

Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

Roche BTK drug emerges as potential breakthrough in primary progressive MS

Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease

Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs

Moderna teams up with Recordati to commercialize rare disease therapy